Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
- Indications Carcinoma; Colon cancer
- Focus Registrational; Therapeutic Use
- Acronyms MOSAIC
- Sponsors Sanofi
- 08 Jun 2021 Results assessing effects of complex treatment regimens (5-fluorouracil (5FU) vs oxaliplatin + 5FU (FOLFOX)) in stage III colon cancer real-world patients using data from randomized MOSAIC trial, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jun 2021 Results of an analysis comparing FOLFOX delivery in this trial and real-world populations using longitudinal cumulative dose presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 16 Jan 2020 Results (n=6501) of pooled analysis of six clinical trials (NCT00079274; NCT00096278; NCT00004931; NCT00275210; NCT00265811; NCT00112918) examining the change of outcomes over 10-year period in patients with stage 3 colon cancer who were treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database, published in the Annals of Oncology.